INTRODUCTION
In mammalian cells, three TET (Ten Eleven Translocation) proteins, TET1, TET2 and TET3, function as methylcytosine dioxygenases, commonly converting methylcytosine (mC) to hydroxymethylcytosine (hmC), which is thought to be an essential intermediate in both active and passive demethylation processes. 1, 2 Furthermore, hmC is also believed to serve as an alternative epigenetic mark to mC in the regulation of gene expression. 3, 4 Nevertheless, its biological function remains unclear. 5 TET2 mutations are frequently found in myeloid malignancies (myelodysplastic syndromes, 14-26%; myeloproliferative neoplasm, 7.6-37% and acute myeloid leukemias, 12-43%). [6] [7] [8] [9] TET2 loss-of-function mutations are associated with aberrant DNA methylation patterns in myeloid malignancies. 10, 11 Of interest here, TET2 mutations are extremely frequent in subtypes of T-cell lymphoma such as angioimmunoblastic T-cell lymphoma (AITL, 30-83%) and peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS, 10-49%). [12] [13] [14] AITL is thought to emerge from follicular helper T (Tfh) cells, based on findings from geneexpression profiling and immunohistochemical staining. 15, 16 Tfh cells exist in the follicles of lymph nodes and spleen, and interact with follicular B cells and antigen-presenting cells. 17, 18 B-cell leukemia/lymphoma 6 (Bcl6) and v-maf avian musculoaponeurotic fibrosarcoma oncogene homolog (cMaf) encode key transcription factors governing Tfh differentiation and proliferation. 19 Tfh cells express co-stimulatory molecules such as programmed cell death 1 (PD1) and inducible T-cell costimulator (Icos), 20 as well as chemokine receptors, such as chemokine (C-X-C motif) receptor 5 (Cxcr5) on the cell surface. [21] [22] [23] [24] [25] PTCL-NOS is a group of heterogeneous T-cell lymphomas, some of which also show Tfhlike features.
Thus far, Tet2 function has been assessed in various knockout/ knockdown mice. Common phenotypes seen following Tet2 loss are increased frequency of the lineage-negative, Sca1-positive and c-Kit-positive (LSK) fraction, enhanced competitive repopulation capacity and skewed differentiation toward myeloid lineages. 14, [26] [27] [28] [29] [30] Some Tet2-knockout mice are reported to develop myeloid malignancies, resembling chronic myelomonocytic leukemia (CMML). 14, 26, 27 Here, we show that Tet2-knockdown mice develop T-cell lymphoma with Tfh-like features. Comprehensive gene expression analysis and DNA methylation and hydroxymethylation analysis revealed epigenetic changes in lymphoma cells.
MATERIALS AND METHODS Mice
Tet2 gene trap mice, in which a poly-A trapping cassette containing the β-galactosidase/neomycin resistance gene is inserted into the second intron, 31 were purchased from TransGenic Inc. (Kumamoto, Japan). Mice were genotyped by tail DNA PCR using the primers listed in Supplementary Table 7 . Mice were backcrossed 48 times onto a C57BL/ 6 background. Experiments were performed according to the Guide for Care and Use of Laboratory Animals at the University of Tsukuba.
Gene expression array analysis
Gene expression analysis was carried out with samples from CD4 + cells from lymphoma-developing Tet2 gt/gt mice or from wild-type (WT) mice with GeneChip Mouse Gene 1.0 ST Array (Affymetrix, Santa Clara, CA, USA), according to the manufacturer's instructions. The Gene Expression Omnibus (GEO) accession number for the microarray data reported in this paper is GSE52430. See Supplementary Methods for more information.
MeDIP and hMeDIP sequencing
MeDIP and hMeDIP sequencing protocols were performed as described, with minor modifications. 32 The DNA Data Bank of Japan (DDBJ) accession numbers are DRA001275 and DRA001277. See Supplementary Methods for more information. See Supplementary information for more methods.
RESULTS

Decreased Tet2 function significantly increases the number of Tfh-like cells in the spleen
We analyzed homozygous Tet2 (hereafter named Tet2 gt/gt ) mice harboring a gene-trap vector in the Tet2 second intron (Supplementary Figure S1a ). 31 We reproduced various findings described in previous papers using the same mice, such as 80% decrease in Tet2 mRNA levels and 50% decrease in hmC levels in fetal liver (FL) lineage-negative cells (Supplementary Figures S1b and c), and enhanced repopulating activity in FL LSK cells only after secondary transplantation ( Supplementary Figures S2a  and b ). 29, 30 Tet2 gt/gt mice were born and grew almost normally at a frequency of a half the expected Mendelian ratio (Tet2 gt/gt : Tet2 +/gt :Tet2 +/+ = 32:124:70). There were no significant differences in appearance, complete blood cell counts and proportions of granulocytes, T cells and B cells in the peripheral blood among Tet2 gt/gt , heterozygous (Tet2 +/gt ) and Tet2 +/+ mice during the period between 40 and 60 weeks of age (Supplementary Figures  S3a and b) .
When evaluated at 40-60 weeks old, the spleen weights of Tet2 gt/gt mice were significantly higher than those of Tet2 +/gt and Tet2 +/+ mice (179.8 ± 72.3 mg, 97.0 ± 10.6 mg and 108.5 ± 26.1 mg, respectively) ( Figure 1a ). One of the 10 Tet2 gt/gt mice developed marked splenomegaly (4300 mg). Hematoxylin-Eosin (HE) staining demonstrated preserved follicular structures, having enlarged germinal centers in some Tet2 gt/gt mice ( Figure 1b ).
Next we used flow cytometry to analyze splenocyte phenotypes and observed no differences in proportions of CD4 + T cells and B220 + B lymphocytes between Tet2 gt/gt , Tet2 +/gt and Tet2 +/+ mice, although the proportion of CD3 + T cells was marginally, but significantly, decreased in Tet2 gt/gt mice compared with those of Tet2 +/+ mice. The population of Gr1 + Mac1 + granulocytes was slightly, but significantly, increased in Tet2 gt/gt mice compared with that of Tet2 +/gt and Tet2 +/+ mice (Figure 1c ). The absolute number of cells was increased in all the fractions of Tet2 gt/gt mice compared with those of Tet2 +/gt and Tet2 +/+ mice ( Figure 1d ). Furthermore, we observed significant increases in the ratios of CD4 + CD44 + PD1 + fraction in Tet2 gt/gt mice compared with those of Tet2 +/gt and Tet2 +/+ mice (Figures 1e and f) . The ratio of CD4 + PD1 + Cxcr5 + fraction was significantly higher in Tet2 gt/gt mice than that in Tet2 +/+ mice (Figure 1f ). The absolute numbers of CD4 + CD44 + PD1 + and CD4 + PD1 + Cxcr5 + fractions were significantly increased in Tet2 gt/gt compared with that in Tet2 +/gt and Tet2 +/+ mice (Figure 1g ). PD1 is a co-stimulatory molecule expressed on Tfh cells, which are in fact marked by co-expression of CD4, PD1 and Cxcr5 in mice. 33 In a similar manner to the analysis above, immunofluorescent staining of spleen tissues also indicated an increase of Tfh-like cells in Tet2 gt/gt mice ( Figure 1h ). Overall, our results indicate that reduced Tet2 function causes outgrowth of Tfh-like cells in the spleen at 40-60 weeks old. Extramedullary hematopoiesis in Tet2-knockout/down mice, as described by others, 14, 26, 27, 30 was not apparent in our analysis, although there was a tendency towards increase in erythroid precursor cells and a statistically significant increase in LSK cells in the spleens of Tet2 gt/gt mice compared with mice of other genotypes (Supplementary Figure S4a ).
Tet2 gt/gt mice develop T-cell lymphoma with Tfh-like features
We next analyzed Tet2 gt/gt mice older than 60 weeks and found that five in seven mice developed marked splenomegaly, multiple swollen lymph nodes and multiple nodules in the liver and lungs (median age, 67 weeks old) (Figures 2a-c) . HE staining showed that follicular structures in spleens of tumor-developing Tet2 gt/gt mice were completely destroyed due to the invasion of large pleomorphic cells exhibiting irregular-shaped nuclei (Figure 2c ). These findings implied that Tet2 gt/gt mice developed lymphoma. We performed immunofluorescent staining to examine the phenotype of the infiltrating cells, demonstrating that most of the cells expressed CD4 + , PD1 + and Cxcr5 + (Figure 2d ). To confirm whether the tumors were T-cell lymphoma, we examined the T-cell receptor (TCR) rearrangement pattern using DNA from CD4 + T cells in tumor-developing spleens and lymph nodes, and found that the tumor-derived CD4 + T cells demonstrated distinct rearrangement patterns in TCR Vβ/Jβ2. Furthermore, tumorderived CD4 + T cells from the spleen and swollen lymph nodes of a mouse showed identical TCR rearrangement patterns (Figure 2e , related to Table 1 ). Thus, we concluded that Tet2 gt/gt mice developed T-cell lymphoma.
Next, we characterized the lymphoma-developing Tet2 gt/gt mice. There were no significant differences in white blood cell count and hemoglobin concentration in the peripheral blood of Tet2 gt/gt , Tet2 +/gt and Tet2 +/+ mice, while platelet count in lymphomadeveloping Tet2 gt/gt mice was significantly lower than that of Tet2 +/+ mice (Figure 3a ). The spleen weight of lymphomadeveloping Tet2 gt/gt mice was significantly higher than that of Tet2 +/gt and Tet2 +/+ mice (1466 ± 1086 mg, 139.3 ± 45.0 mg, and 165 ± 83 mg, respectively) ( Figure 3b ). In the spleens, the CD4 + helper T-cell fractions were significantly increased in Tet2 gt/gt mice compared with those of Tet2 +/gt and Tet2 +/+ mice (Figure 3c ). The B220 + B-cell fraction was significantly decreased in Tet2 gt/gt mice compared with that of Tet2 +/+ mice. There was no significant difference in Gr1 + /Mac1 + myeloid cell fraction. The CD4 + T cells were mostly positive for CD44 and PD1, and to a lesser extent for Cxcr5 ( Figure 3d ). The percentage of CD4 + PD1 + Cxcr5 + Tfh-like cell fraction was significantly higher than that of mice with the other genotypes. There were no differences in the erythroid precursor and LSK fraction in the spleens between the aged Tet2 +/+ and Tet2 +/gt mice (Supplementary Figure S4b ).
In the clinical setting, AITL patients often show polyclonal hypergammaglobulinemia. Serum immunoglobulin levels in both Tet2 +/+ mice and Tet2 gt/gt mice, however, did not show significant difference (Supplementary Figure S5) .
Taken together, these results indicate that Tet2 gt/gt mice develop T-cell lymphomas that exhibit features characteristic of Tfh-like cells, but these T-cell lymphomas do not show pathological or clinical findings relevant to human AITL. PTCL-NOS with Tfh-like features 13 might be the closest counterpart.
Lymphoma cells exhibit gene expression profiles similar to those of Tfh cells
Gene-expression profiles of CD4 + cells derived from splenic tumors of Tet2 gt/gt mice versus CD4 + cells from normal WT spleen (hereafter designated lymphoma cells versus control CD4 + cells, respectively) were evaluated using the Kyoto Encyclopedia of Genes and Genomes (KEGG) resource 34 and Gene Set Enrichment Analysis (GSEA). 35 When 903 upregulated genes (42 folds) and 896 downregulated genes (o 0.5 folds) were searched, the KEGG brought up enriched terms such as 'cytokine-cytokine interaction' and 'hematopietic cell lineage and immune response' (Supplementary Tables S1 and S2). For the GSEA, the Tfh-upregulated gene set was unavailable in BIOCARTA and thus had to be newly made by selecting 21 genes based on previous microarray analyses. 36, 37 The Th1/Th2 pathway gene sets were adopted from BIOCARTA for GSEA analysis. The Tfh-upregulated genes were significantly enriched in lymphoma cells compared with control CD4 + cells (P-value 0.0020, FDR Q-value 0.0027, NES 1.869) ( Figure 4a ). In contrast, genes associated with Th1/2 differentiation were enriched in control CD4 + cells (P-value = 0.0169, FDR Q-value = 0.0169, NES − 1.702) ( Figure 4b ).
To validate the Tfh-like signature in lymphoma cells, we Transcript levels of all these molecules were significantly higher in lymphoma than control CD4 + cells (Figure 4c ). In contrast, transcript levels of Tbx21 and Gata3, which encode master transcription factors regulating Th1 and Th2 differentiation, respectively, were comparable or slightly lower in lymphoma (Figure 4d ). In addition, immunofluorescent staining revealed many cells were co-stained for CD4 and Bcl6 or cMaf in lymphoma-developing spleen tissue (Figure 4e ).
Lymphoma cells exhibit genome-wide aberrant methylation and hydroxymethylation patterns
To examine potential epigenetic changes in lymphoma cells, we performed methylated DNA immunoprecipitation (MeDIP) and hydroxymethylated DNA immunoprecipitation (hMeDIP) combined with high-throughput sequencing, using three independent samples for lymphoma and control CD4 + cells. In the geneoriented analysis, the average level of mC showed a similar pattern in the lymphoma cells and control CD4 + cells, while the hmC level was slightly reduced in lymphoma cells. Focused around the TSS, the average mC level showed a slight decrease just downstream of the TSS, but an increase toward its gene body region in lymphoma cells. In comparison, the decrease of average hmC level was remarkable between TSS and at 5 k bp downstream of TSS in lymphoma cells (Figure 5a ). We then examined the distribution of the highly enriched regions of mC and hmC. The regions in which the Model-based analysis for ChIP-Seq (MACS) score was 45 were considered to be highly enriched regions. 38 Within these regions, methylation at the TSS regions (TSS ± 1 k bp, TSS ± 5 k bp), gene bodies and CpG islands was increased in lymphoma cells in comparison with the control CD4 + cells (P = 0.013, 0.006, 0.006 and 0.022, respectively). Hydroxymethylation was decreased at the TSS regions in lymphoma cells Figure 5b ). Next, we merged the two gene lists, the first for upregulated gene expression and the second for aberrant deposition of methylation or hydroxymethylation. Generally, DNA methylation in the promoter region is closely associated with the inactivation of gene expression. In contrast, aberrant accumulation of methylation in the gene body is known to be associated with upregulated transcription. 39 The tumor cells in our T-cell lymphoma mouse model showed Tfh-like cell outgrowth and lymphoma cells showed upregulation in the Tfh-related genes. Thus, we selected 2555 genes (upper 10% of total genes) showing greater mC density at the gene body regions in lymphoma cells compared with the control CD4 + cells (mean difference of tag counts by MACS 47) . Independently, we selected 2500 highly expressed genes (upper 10% of total genes), and the top 903 genes with an expression fold of 42 in lymphoma cells compared with control CD4 + cells. In these two groups, 448 and 118 genes, respectively, fulfilled both criteria of mC increase in gene body and fold change in gene expression. Gene ontology (GO) analysis picked up several enriched terms associated with oncogenesis, such as regulation of cell death and anti-apoptosis for the 448 genes ( Supplementary Table S3 ), and cell division, cell cycle and cell cycle process ( Supplementary Table S4 ) for the 118 genes (Figure 5c ).
We similarly selected 2639 genes (upper 10% of total genes) (mean difference of tag counts by MACS o − 3) showing lower hmC density at the TSS ± 1 k bp regions in lymphoma cells showing increased methylation at the gene body in lymphoma cells compared with control CD4 + cells were selected, as were the top 2500 and 903 genes showing higher expression in lymphoma compared with control CD4 + cells; 448 and 118 genes were common to both groups, respectively. Gene ontology (GO) analysis was performed using these genes. Each term was shown. (d) The top 2639 genes showing decreased hydroxymethylation in the gene body in lymphoma cells compared with control CD4 + cells were selected, as were the top 2500 and 903 genes showing higher expression in lymphoma compared with control CD4 + cells. 248 and 57 genes were common to both groups, respectively. GO analysis was performed using these genes.
TET2 knockdown mice developed T-cell lymphoma H Muto et al compared with the control CD4 + cells, in light of a recent report demonstrating that hmC at the promoter region negatively regulates gene expression. 40 When the same 2500 and 903 highly expressed genes were analyzed, 248 and 57 genes, respectively, fulfilled both criteria of hmC increase at TSS − 1 k bp and fold change in gene expression ( Figure 5d ). GO analysis picked up enriched terms such as immune response and regulation of lymphocyte activation ( Supplementary Table S5 ), and cell death and death ( Supplementary Table S6 ) for the 248 and 57 genes, respectively. These analyses suggest that the gene list overlapping highly methylated genes at the gene body and upregulated genes in lymphoma cells is linked to oncogenesis, and that the gene list overlapping less hydroxymethylated genes at TSS and upregulated genes in lymphoma cells is linked to the immune system.
Bcl6 was one of the 448 genes associated with mC change that arose in our analyses of the Tfh-related genes enriched in lymphoma cells. MeDIP sequencing of the Bcl6 locus revealed a markedly increased mC density in the first intron in lymphoma compared with the control CD4 + cells (Figure 6a ). The change in the mC density in the first intron was validated by quantitative MeDIP (qMeDIP) (Figure 6b ). hmC analysis as described above revealed PD1 and Cxcr5 to be among the Tfh-related genes. hmC peaks were decreased in TSS ± 1 k bp of PD1 and Cxcr5 genes Supplementary Figures S6a and S6c ). Quantitative hMeDIP also showed tendencies of hmC decrease in TSS ± 1 k bp of both genes, but there was no statistical significance (Supplementary Figure S6b and S6d).
These results prompted us to further analyze the first intron of the Bcl6 gene, which has been reported as an intronic silencer region (Bcl6 int1-S), the silencing activity of which depends on its methylation status in a human B-cell lymphoma cell line. 41 BCL6 plays a definitive role for the development of Tfh cells. 20 Bisulfite sequencing revealed an increase in the density of modified cytosine at the first intron in lymphoma relative to control cells (Figure 6c ), corresponding to the MeDIP sequencing (Figure 6a ).
Decitabine-induced demethylation of the first intron of Bcl6 decreases mRNA expression in EL4 cells
To determine whether methylation-dependent regulation of Bcl6 expression occurs in T-lineage lymphoma cells, we examined Bcl6 mRNA expression and methylation status in EL4 cells, a mouse T-cell lymphoma cell line. Bisulfite sequencing revealed that almost all cytosines found in CpG sequences were methylated at the Bcl6 int1-S in EL4 cells. Following treatment of EL4 cells with the demethylating agent decitabine, levels of the methylated cytosines decreased (Figure 6d ). Accordingly, Bcl6 transcript levels decreased in a decitabine dose-dependent manner (Figure 6e ). This result supports the notion that the methylated cytosine density at the Bcl6 int1-S positively regulates Bcl6 transcription in T cells.
Frequently coexisting mutations with TET2 mutation in hematologic malignancies are not detected by exome and targeted sequencing To examine additional mutations in lymphoma cells, we performed exome sequencing in the lymphoma cells developed in Tet2 gt/gt mice (sample No.5 in Table 1 ). Five gene mutations were identified and validated by Sanger sequencing, but none of these mutations have been reported in connection with human peripheral T-cell lymphoma ( Table 2) . 12, 42, 43 In contrast, Flt3, Npm1, Dnmt3a, Idh2 and Rhoa mutations, which are known to coexist with TET2 mutations in various human hematologic malignancies, were not identified by targeted sequencing in tumor sample numbers 1 to 5 (Supplementary Figure S7) .
DISCUSSION
Here, we report a new mouse model of T-cell lymphoma with Tfhlike features and a long latency following proliferation of nonneoplastic Tfh-like CD4 + T cells. Reduced Tet2 function possibly contributes to perturbed conversion of mC to hmC, an essential intermediary in the demethylation process. Genome-wide methylation analysis of lymphoma cells revealed an abnormal accumulation of mC. Further analysis suggested that one of the important targets for Tfh-like cell outgrowth might be an increase of methylation level at Bcl6 int1-S.
Heterozygous mutations in the Roquin gene, which encodes a protein that binds to and reduces the stability of Icos mRNA, also promotes T-cell lymphoma accompanied by Tfh features in mice. Roquin mutations, however, have not been identified in human AITL samples. 12, [44] [45] [46] Given this, our mouse model recapitulates human T-lymphomagenesis more closely than the Roquin model. Nevertheless, other characteristics of human AITL, such as polyclonal hypergammaglobulinemia, proliferation of high endothelial venules, and infiltration of eosinophils and B cells, were not seen. Our model mimics PTCL-NOS with Tfh-like features in humans.
Bcl6 has been reported to direct Tfh-cell differentiation. 20 Bcl6deficient T cells fail to develop into Tfh cells and cannot sustain germinal center responses, whereas forced expression of Bcl6 in CD4 + T cells promotes expression of Cxcr5 and PD1, which encodes Tfh-cell markers. Furthermore, transgenic mice constitutively expressing Bcl6 protein in lymphocytes develop B-and T-cell lymphomas. In this model, lymphoma development required a long latency period, and the incidence was markedly enhanced by administration of N-ethyl-N-nitrosourea (ENU), which is known to induce DNA mutations. 47 In this paper we have shown that Tet2 gt/gt mice develop lymphoma with a long latency, similar to Bcl6 transgenic mice. Thus, impaired Tet2 or enhanced Bcl6 in isolation might induce a premalignant state, but be insufficient to induce lymphoma development in mice. Given that TET2 somatic mutations occur in 5.6% of elderly females with skewed X-inactivation without hematological malignancies, 48 additional mutations may be required for lymphoma development. We recently reported that 38 out of 46 (82.6%) clinical AITL samples had mutations in TET2 throughout the coding region, and that 32 out of the 46 (69.5%) samples had mutations in both TET2 and ras homology family A (RHOA). 12 The RHOA mutations were accumulated in amino-acid position 17. Other groups also reported the high frequency of RHOA mutations in AITL patients. 42, 43 In our mouse lymphoma samples, however, the G17 RHOA mutation was not detected, as well as any other frequently coexisting mutations with TET2 mutations in human hematological malignancies. Genomic evolution of T-cell lymphoma in our mouse model was different from that in humans.
DNA derived from AML samples harboring mutations in IDH1/2, which regulates TET2 function, is hypermethylated. 10 DNA from diffuse large B-cell lymphoma samples harboring TET2 mutations also shows hypermethylation. 49 In contrast, hydroxymethylation status has not been widely assessed in any hematologic malignancies. It is known that hmC is particularly enriched at TSS regions of genes in ES cells, 50 suggesting that hmC functions in transcriptional regulation. The marked hmC reduction at TSS regions of lymphoma cells reported here suggests that impaired TET2 function might alter transcription via reduction in the hmC epigenetic mark, in addition to impaired demethylation.
In summary, we conclude that Tet2 gt/gt mice develop T-cell lymphoma with Tfh-like features with epigenetic changes. Hypermethylation of Bcl6 int1-S possibly contributes to the upregulation of Bcl6 and outgrowth of Tfh-like cells. Demethylating agents, such as azacitidine and decitabine, are reportedly effective for treating MDS. 51, 52 These agents may also possibly target T-cell lymphomas, particularly those that harbor mutations in epigenetic regulators. 
